Insulin modifier and preparation method and application thereof

Abstract

The invention discloses an insulin modifier, comprising insulin and a fatty acid chain which is connected to the tail end of an insulin B chain, wherein the insulin is swine insulin or dog insulin; alanine at the 30th bit of the insulin B chain is cut off; the insulin and the fatty acid chain are connected by an amido bond. The insulin modifier can form an oelophilic group to promote longitudinal sorting of insulin protein, so as to form an intermolecular force-dominant chain polyethylene polymer due to the hydrophobic effect of the long fatty acid chain after the insulin modifier enters the body. Compared with monomer insulin, the half-life period of the polyethylene polymer is greatly prolonged; the polyethylene polymer has a good slow-release effect; meanwhile, the insulin modifier does not contain other protein with immunogenicity, and is high in safety performance. The invention also discloses a preparation method of the insulin modifier.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to an insulin modification and its preparation method and application. Background technique [0002] A statistic in 1999 (data from Veterinary Medical Database VMDB) showed that the incidence of diabetes in dogs and cats rose from 0.2% to 1% during the 28 years from 1970 to 1998, and the upward trend became more and more obvious. Almost 100% of dogs and 50% of cats are type I (insulin dependent) diabetic. The other 50% of cats have type 2 (non-insulin dependent) diabetes. Among the many methods of treating diabetes, insulin injection is the most important and direct method. Since its successful clinical application in 1922, insulin has experienced 80 years of development. The original first-generation insulin was extracted from animals (pigs / cows). By 1942, the second-generation insulin was biosynthesized with human sequence insulin through systems such as E. Amino acid subs...

AI Technical Summary

Problems solved by technology

However, the effects of the above two slow-release mechanisms are limited, and their onset time is between 14-24 hours, which is not convenient enough as a pet product.

In addition, the instability of the crystalline state of Vetsulin and the immunogenicity of Prozinc protamine may affect the safe use of the drug

[0006] Therefore, there is not yet a kind of insulin modification with good sustained release effect and high safety performance for the treatment of animal diabetes.

Images